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ABSORB EXTEND: An Interim Report on the 36-month Clinical Outcomes
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Background: The safety and performance of the current Absorb Bioresorbable
Vascular Scaffold (Absorb BVS) (Abbott Vascular, Santa Clara, CA) has been pre-
viously established in 101 patients from Cohort B of the First-in-Man ABSORB trial.
At 48 months, the MACE rate in Cohort B was 10.1%, with no scaffold thrombosis
reported. ABSORB EXTEND was initiated as a global continued access study
(outside of the US) to expand experience with the Absorb BVS to different geogra-
phies. Additionally, patients were allowed to be treated for longer coronary lesions
and smaller vessels than those in the Cohort B trial, using either longer scaffold
lengths or planned overlap with the 2.5 and 3.0 mm Absorb BVS.
Methods: ABSORB EXTEND is a prospective, single-arm, open-label clinical study
that enrolled 812 subjects at 58 sites. Included were patients with lesions  28 mm in
length and reference vessel diameter of 2.0 - 3.3 mm (as assessed by on-line QCA or
IVUS). Treatment of a maximum of two de novo native coronary artery lesions, each
in a different epicardial vessel, was permitted.
Results: Interim 24-month data in the ﬁrst 250 ABSORB EXTEND study patients has
been previously presented. Patients included 33% with unstable angina, 29% with
prior MI and 27% with diabetes mellitus. The mean RVD was 2.610.35 mm and
mean lesion length was 11.61 mm. In these 250 patients, the hierarchical MACE, TVF
and def/prob ST rates at 2 year were 7.3%, 8.1% and 0.8% respectively. Long-term,
36-month follow-up data will be presented for these patients and will provide sub-
stantial data on the long-term safety and performance of the Absorb BVS in a larger
population of patients, including those with planned overlapping and dual vessel
treatment. Furthermore, a propensity score matched comparison with Xience treated
patients from the SPIRIT trials will be presented.
Conclusions: Long-term outcomes in approximately 250 patients at 36 months (the
largest patient cohort reported at this time point to date) from ABSORB EXTEND will
provide further insight into the safety and performance of the Absorb BVS.
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Background: Bioresorbable vascular scaffold (BVS) implantation has been suggested
to induce a tissue response separating potentially thrombogenic plaque components
from the lumen, thus ’sealing’ the plaque. Attenuation is an optical property of tissues
that can be measured in optical coherence tomography (OCT) images. High attenu-
ation is associated with necrotic core or macrophages, whereas lower attenuation
values correspond to more benign phenotypes. We analysed the attenuation properties
of a segment treated with BVS 5 years post implantation.
Methods: 8 of 14 living patients enrolled of the Thoraxcenter cohort of ABSORB
A, underwent additional OCT follow-up, 5 years post BVS implantation. The 5-
year OCT images were examined with attenuation analysis. Attenuation was
quantiﬁed at the treated segment circumferentially by custom-made software 1) at
the entire depth of the plaque and 2) at a superﬁcial signal-rich layer after manual
segmentation.
Results: The mean attenuation value within the ’sealing layer’ was 1.770.32mm-1
and the median was 1.280.25mm-1. This value was higher within the entire ’neo-
plaque’ (mean: 2.870.54mm-1, median: 2.330.49 mm-1, p< 0.001). Spread-out
attenuation maps at different depths from the luminal surface are displayed in the
Figure. The surface layers (ﬁrst 200mm) had low attenuation, overlying high-attenu-
ation areas located deeper in the plaque.B180 JACC Vol 64/11/Suppl B j September 13–1Conclusions: At long-term BVS follow-up, attenuation analysis conﬁrms the ﬁnding
in most cases of a superﬁcial homogeneous layer with low attenuation, unlikely to
contain high-risk wall components such as necrotic core and macrophages.
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Background: Current bioresorbable scaffold technology has shown promising results
in small-sized clinical studies. However, preclinical data addressing long-term
vascular reactions remain limited. The aim of this study was to investigate vascular
responses of a novel bioresorbable polymeric scaffold (BRS) (PLA; Arterial
Remodeling Technologies, Paris, France) by histology and optical coherence to-
mography (OCT) compared with bare-metal stent (BMS; Vision, Abbott Vascular,
Santa Clara, CA, USA) in porcine coronary arteries.
Methods: A total of 107 devices (54 BRS and 53 BMS) were implanted in miniature
swine coronary arteries and examined by OCT at follow-up of 30-, 90-, 180-, 270-,
365-, 545-, and 720-days (22 BRS and 20 BMS) and all were examined by light
microscopy at each time point.
Results: Lumen area was signiﬁcantly smaller in BRS than BMS at 30-, and 90-days.
Although neointima area was increasing over time in BRS, lumen area also pro-
gressively increased after 90 days whereas in BMS luminal gain was not observed.
Inﬂammation score was greater in BRS compared to BMS at 3- to 24-months. Peak
degradation of stent struts was observed between 3 to 9 months. While BRS showed a
signiﬁcant positive correlation between lumen area and inﬂammation score from 1 to
9-months, a negative correlation was observed in BMS (ﬁgure).
Conclusions: This study shows positive remodeling of coronary vessels treated with
BRS with increasing lumen area over time. Lumen area enlargement was associated
with inﬂammation reaction during peak degradation.7, 2014 j TCT Abstracts/Stents - Drug-eluting: Bioresorbable Scaffolds
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Background: The ABSORB Cohort A trial results demonstrated the safety of
Absorb BRS (Abbott Vascular, Santa Clara, CA, USA) in 30 patients with single
de novo native coronary artery lesions, with a low long-term MACE rate at 5
years (3.4%) and no scaffold thrombosis. Non-invasive MSCT imaging at 5
years conﬁrmed the patency of the vessels with a non-signiﬁcant decrease in
plaque area. The ABSORB Cohort B trial, a continuation of that assessment with
a modiﬁed Absorb BRS, enrolled 101 patients at 12 sites in Europe and Asia
Paciﬁc.
Methods: The patients of the ABSORB Cohort B trial were divided into 2 groups,
Cohort B1 (45 patients) having imaging follow-up performed at 180 days, 2 years and
5 years and Cohort B2 (56 patients) having imaging follow-up performed at 1, 3 years
and 5 years.Five-year data for Cohort B1 are currently being collected.
Results: In the ABSORB Cohort B trial, the mean age was 62 years. Patients with
diabetes: 17%, hypertension: 66%, hypercholesterolemia: 85%, family history of
CAD: 55%, stable angina: 68%, of which 15% having stable angina with CCS
classiﬁcation of III or IV. Patients with unstable angina: 15%, 2% with unstable
angina of Braunwald Class III. Lesion location was RCA (33%), LAD (43%), LCX
(22%) and Ramus (1%), with ACC/AHA lesion classiﬁcation of B1 for 55%, B2
for 40% and C for 4%. In Group B2, late loss at 3 years was 0.29  0.43mm,
unchanged from 1 year (0.27 0.34mm) and vasomotion, as a response to nitro-
glycerine injection, was demonstrated. Quantitative IVUS results revealed mean
scaffold area and mean lumen area enlargement between baseline and 3 years. The
scaffold enlargement at 3 years was conﬁrmed by OCT. At 3 years, the strut cores
were still visible on OCT, which is in line with earlier pre-clinical data showing
that the scaffold is biodegraded and replaced by provisional matrix at 3 years.
Hypothetically, due to the integration process after bioresorption, further lumen
enlargement as well as wall thinning could be expected at later time points.
Clinical data up to 4 years showed an ID-MACE rate of 10.1% with no events of
scaffold thrombosis.
Conclusions: The long-term 5-year QCA and vasomotion results for Cohort B1 will
be presented.TCT-620
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Background: Previous ABSORB studies proved safety and efﬁcacy of bioresorbable
vascular scaffolds (BVS, Abbott Vascular Inc., Santa Clara, CA) under clinical study
conditions. However, in a real world setting including patients with a worse health
status, a higher proportion of complex lesions and waiving obligatory IVUS or OCT
guidance, BVS treatment has not been evaluated. For this purpose, we set up the
ASSURE registry over a period of 3 years.
Methods: Unselected, consecutive patients with de novo native coronary artery dis-
ease were enrolled at 6 German centers in the prospective, observational registry.
Outcomes were procedural success and occurrence of cardiovascular death, myocar-
dial infarction, ischemia driven target lesion revascularization, and target vessel failure
or revascularization. Angiographic parameters including independent quantitative
coronary angiography were assessed pre and post procedure. One-year experience is
being reported.
Results: A total of 183 patients (198 lesions) were treated with BVS. In 128
(64.7%) lesions a complex ACC/AHA morphology (B2 or C) was present. Proce-
dural success was achieved in all patients. Acute gain of minimal lumen diameter
was 1.54  0.51 mm. Through 12 months, 1 patient (0,5%) died from gastroin-
testinal bleeding, 3 (1.7%) non-target vessel myocardial infarctions occurred, and 5
(2.8%) target lesion revascularizations (TLR) had become necessary because of in-
scaffold restenosis. No scaffold thrombosis occurred. The 12-month MACE inci-
dence of 5.0% was in the same range as in previous BVS studies (4.2% in ABSORB
Cohort B; 6.9% in ABSORB EXTEND preliminary data from 450 patients) and in
everolimus eluting metallic stent trials (4.1% in SPIRIT IV). At 12 months, angina
pectoris was less frequent (17.3% versus 56.8%), as was unstable angina pectoris
(1.7% versus 21.3%).
Conclusions: One-year ASSURE results suggest that BVS for de novo coronary ar-
tery disease are associated with favorable clinical and functional outcomes in all day
clinical practice without mandatory IVUS or OCT guidance (ClinicalTrials.gov:
NCT01583608).TCT-621
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Background: There is limited outcome data on the use of the ABSORB bioresorbable
vascular scaffold (BVS) in daily clinical practice, in particular in acute coronary
syndrome (ACS) patients and more complex lesions. The aim of this study was to
evaluate the clinical outcome after BVS implantation in both simple and complex
lesions in stable patients and acute coronary syndrome patients, similar to a more “real
world” population.
Methods: All patients assigned to treatment with BVS between August 2012 and
August 2013 were included in this single center registry. 12-month clinical outcomes
assessed were cardiac death, myocardial infarction (MI), stent thrombosis (ST), target
lesion revascularization (TLR), target vessel revascularization (TVR) and target vessel
failure (TVF). TVF was deﬁned as a composite of the device oriented endpoints of all-
cause mortality, any MI or TVR.
Results: A total of 135 patients (59  11 years, 73% male, 20% diabetic) were
enrolled and 159 lesions were treated. Stable angina was the indication for PCI in
47%, and ST-segment elevation myocardial infarction (STEMI) in 13%. The majority
of the lesions (67%) were lesion type B2 or C (AHA/ACC classiﬁcation), including 2
left main, 13 chronic total occlusions and 24 bifurcation lesions. Median follow-up
duration was 378 days [Q1-Q3: 201-435]. At twelve months the individual clinical
endpoint of cardiac death occurred in one patient (12-month cumulative event rate
0.8%), MI in 5 (4.3%), TLR in 11 (9.8%) and TVR in 14 (12.0%). ST occurred in 4
patients (12-month cumulative deﬁnite ST rate of 3.0%). All cases of ST were
angiographic deﬁned as deﬁnite, including three sub-acute and one late-ST. In sum-
mary, the composite endpoint of TVF occurred in 15 patients resulting in a 12-month
cumulative event rate of 13.2%.
Conclusions: Based on the results of the current study we believe that implantation of
the ABSORB BVS in a “real world” patient population is applicable and associated
with acceptable clinical outcomes at twelve months. Complete 12-month follow-up
results will be available at TCT 2014.nts - Drug-eluting: Bioresorbable Scaffolds B181
